Sharon Wilks

4.4k total citations
49 papers, 950 citations indexed

About

Sharon Wilks is a scholar working on Oncology, Pulmonary and Respiratory Medicine and Cancer Research. According to data from OpenAlex, Sharon Wilks has authored 49 papers receiving a total of 950 indexed citations (citations by other indexed papers that have themselves been cited), including 38 papers in Oncology, 20 papers in Pulmonary and Respiratory Medicine and 18 papers in Cancer Research. Recurrent topics in Sharon Wilks's work include HER2/EGFR in Cancer Research (23 papers), Cancer Treatment and Pharmacology (20 papers) and Advanced Breast Cancer Therapies (17 papers). Sharon Wilks is often cited by papers focused on HER2/EGFR in Cancer Research (23 papers), Cancer Treatment and Pharmacology (20 papers) and Advanced Breast Cancer Therapies (17 papers). Sharon Wilks collaborates with scholars based in United States, Serbia and United Kingdom. Sharon Wilks's co-authors include Ruth O’Regan, Joyce O’Shaughnessy, Donald Richards, Joyce O’Shaughnessy, Virginia Kaklamani, Sara A. Hurvitz, Masakazu Toi, Guy Jérusalem, Claudine Isaacs and Fabrice André and has published in prestigious journals such as Journal of Clinical Oncology, SHILAP Revista de lepidopterología and Cancer Research.

In The Last Decade

Sharon Wilks

47 papers receiving 928 citations

Peers

Countries citing papers authored by Sharon Wilks

Since Specialization

Citations

This map shows the geographic impact of Sharon Wilks's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Sharon Wilks with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Sharon Wilks more than expected).

Fields of papers citing papers by Sharon Wilks

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Sharon Wilks. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Sharon Wilks. The network helps show where Sharon Wilks may publish in the future.

Co-authorship network of co-authors of Sharon Wilks

This figure shows the co-authorship network connecting the top 25 collaborators of Sharon Wilks. A scholar is included among the top collaborators of Sharon Wilks based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Sharon Wilks. Sharon Wilks is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

#	Work	Indexed citations
1	Long-Term Safety and Efficacy of the Fixed-Dose Combination of Pertuzumab and Trastuzumab for Subcutaneous Injection in Patients With HER2-Positive Early Breast Cancer in PHranceSCa, a Randomized, Open-Label Phase II Study 2025 ·Clinical Breast Cancer ·Joyce O’Shaughnessy, Susana Sousa, Josefina Cruz Jurado, Lesley Fallowfield, Päivi Auvinen, (unknown), Ana Cvetanović, Sharon Wilks, (unknown), Mauricio Burotto, Thomas Boulet, (unknown), (unknown), Peter C. Trask, (unknown), (unknown), Ljiljana Stamatović	0
2	97P Efficacy and safety of the fixed-dose combination of pertuzumab and trastuzumab for subcutaneous injection in patients with HER2-positive early breast cancer: Long-term data from the PHranceSCa study 2023 ·ESMO Open ·Joyce O’Shaughnessy, (unknown), Josefina Cruz Jurado, Lesley Fallowfield, Päivi Auvinen, (unknown), Ana Cvetanović, Sharon Wilks, (unknown), Mauricio Burotto, Thomas Boulet, (unknown), (unknown), Peter C. Trask, (unknown), (unknown), (unknown)	1
3	A phase 1, first-in-human, open-label, dose escalation and dose expansion study of TST005 in patients with locally advanced or metastatic solid tumors. 2023 ·Journal of Clinical Oncology ·Anthony W. Tolcher, Xiaohua Wu, Jian Zhang, Minal Barve, Nashat Gabrail, David Sommerhalder, (unknown), Sharon Wilks, Yong Wu, Rujiao Liu, Shuiping Gao, (unknown), (unknown), Caroline Germa, (unknown), (unknown), Steven Yu, Jenny Yao, Xuelian Zhu	5
4	762 A first-in-human phase 1 clinical study evaluating safety, tolerability, pharmacokinetics, pharmacodynamics and efficacy of the EDB+FN targeting ADC PYX-201 in participants with advanced solid tumors 2023 ·SHILAP Revista de lepidopterología ·Sharon Wilks, Benedito A. Carneiro, Gregory M. Coté, Jason T. Henry, Shiraj Sen, Alexander I. Spira, Frank Tsai, (unknown), Marsha Crochiere, Shui He, (unknown), (unknown), Bin Zhang, Anthony W. Tolcher	1
5	Trilaciclib Prior to Chemotherapy in Patients with Metastatic Triple-Negative Breast Cancer: Final Efficacy and Subgroup Analysis from a Randomized Phase II Study 2021 ·Clinical Cancer Research ·Antoinette R. Tan, Gail S. Wright, Anu Thummala, Michael Danso, Lazar Popović, Timothy Pluard, Hyo S. Han, Željko Vojnović, Nikola Vasev, Ling Ma, Donald Richards, Sharon Wilks, Dušan Milenković, Jie Xiao, Jessica A. Sorrentino, Janet K. Horton, Joyce O’Shaughnessy	28
6	Eribulin Plus Pembrolizumab in Patients with Metastatic Triple-Negative Breast Cancer (ENHANCE 1): A Phase Ib/II Study 2021 ·Clinical Cancer Research ·Sara M. Tolaney, Kevin Kalinsky, Virginia Kaklamani, David R. D’Adamo, Gursel Aktan, Michaela L. Tsai, Ruth O’Regan, Peter A. Kaufman, Sharon Wilks, Eleni Andreopoulou, Debra A. Patt, Yuan Yuan, Grace Wang, (unknown), Dongyuan Xing, (unknown), Vassiliki Karantza, Sami Diab	90
7	Phase I Study of Elacestrant (RAD1901), a Novel Selective Estrogen Receptor Degrader, in ER-Positive, HER2-Negative Advanced Breast Cancer 2021 ·Journal of Clinical Oncology ·Aditya Bardia, Virginia Kaklamani, Sharon Wilks, Amy Weise, Donald Richards, Wael A. Harb, Cynthia R. Osborne, Robert Wesolowski, Meghan Karuturi, Paul Conkling, Rebecca G. Bagley, Yamei Wang, Maureen G. Conlan, Peter Kabos	67
8	259P Weekly ladiratuzumab vedotin monotherapy for metastatic triple-negative breast cancer 2021 ·Annals of Oncology ·(unknown), Heon Han, (unknown), (unknown), (unknown), Lajos Pusztai, Sara A. Hurvitz, Sharon Wilks, (unknown), Rita Nanda, Monica Mita, Joyce O’Shaughnessy, IE Krop, Diana C. Medgyesy, (unknown), Shanu Modi, (unknown), Shikai Wu, Phillip M. Garfin, H.A. Burris	23
9	80O Patient (pt) preference and satisfaction with the subcutaneous fixed-dose combination of pertuzumab (P) and trastuzumab (H) in pts with HER2-positive early breast cancer (HER2+ eBC): Interim analysis of the open-label, randomised cross-over PHranceSCa study 2020 ·Annals of Oncology ·Joyce O’Shaughnessy, (unknown), Juan Jesús Cruz, Lesley Fallowfield, Päivi Auvinen, (unknown), Ana Cvetanović, Sharon Wilks, (unknown), Mauricio Burotto, Dirk Klingbiel, Dimitri Messeri, (unknown), Peter C. Trask, (unknown), (unknown)	3
10	165MO Patient (pt) preference for the pertuzumab-trastuzumab fixed-dose combination for subcutaneous use (PH FDC SC) in HER2-positive early breast cancer (EBC): Primary analysis of the open-label, randomised crossover PHranceSCa study 2020 ·Annals of Oncology ·Joyce O’Shaughnessy, Susana Sousa, Juan Jesús Cruz, Lesley Fallowfield, Päivi Auvinen, (unknown), Ana Cvetanović, Sharon Wilks, (unknown), Mauricio Burotto, Dirk Klingbiel, Dimitri Messeri, (unknown), Peter C. Trask, (unknown), (unknown), (unknown)	6
11	Health-related quality of life in patients receiving first-line eribulin mesylate with or without trastuzumab for locally recurrent or metastatic breast cancer 2019 ·BMC Cancer ·Lee S. Schwartzberg, Kristi McIntyre, Sharon Wilks, Shannon Puhalla, Joyce O’Shaughnessy, (unknown), Yaohua He, Linda T. Vahdat	5
12	Trilaciclib plus chemotherapy versus chemotherapy alone in patients with metastatic triple-negative breast cancer: a multicentre, randomised, open-label, phase 2 trial 2019 ·The Lancet Oncology ·Antoinette R. Tan, Gail S. Wright, Anu Thummala, Michael Danso, Lazar Popović, Timothy Pluard, Hyo S. Han, Željko Vojnović, Nikola Vasev, Ling Ma, Donald Richards, Sharon Wilks, Dušan Milenković, Yang Zhao, Joyce Antal, Shannon R. Morris, Joyce O’Shaughnessy	86
13	Evaluation of Miracle Mouthwash plus Hydrocortisone Versus Prednisolone Mouth Rinses as Prophylaxis for Everolimus-Associated Stomatitis: A Randomized Phase II Study 2019 ·The Oncologist ·Vicky Jones, Kristi McIntyre, Devchand Paul, Sharon Wilks, (unknown), Scot Sedlacek, Anton Melnyk, (unknown), Yunfei Wang, (unknown), Joyce O’Shaughnessy	15
14	nab-Paclitaxel plus carboplatin or gemcitabine versus gemcitabine plus carboplatin as first-line treatment of patients with triple-negative metastatic breast cancer: results from the tnAcity trial 2018 ·Annals of Oncology ·Denise A. Yardley, Rob Coleman, Pierfranco Conté, Javier Cortés, Adam Brufsky, Mikhail Shtivelband, Robyn R. Young, Carmelo Bengala, Haythem Ali, (unknown), Andreas Schneeweiß, Luis de la Cruz‐Merino, Sharon Wilks, Joyce O’Shaughnessy, Stefan Glück, (unknown), Judith Miller, Débora Barton, Nadia Harbeck	91
15	Ixabepilone and Carboplatin for Hormone Receptor Positive/HER2-neu Negative and Triple Negative Metastatic Breast Cancer 2017 ·Clinical Breast Cancer ·Cynthia Osborne, (unknown), Charles F. Eisenbeis, Frankie A. Holmes, Marcus A. Neubauer, (unknown), (unknown), S. Vukelja, Sharon Wilks, Mary Ann Allison, (unknown), Scot Sedlacek, Yunfei Wang, Lina Asmar, Joyce O’Shaughnessy	7
16	Molecular Alterations and Everolimus Efficacy in Human Epidermal Growth Factor Receptor 2–Overexpressing Metastatic Breast Cancers: Combined Exploratory Biomarker Analysis From BOLERO-1 and BOLERO-3 2016 ·Journal of Clinical Oncology ·Fabrice André, Sara A. Hurvitz, Angelica Fasolo, Ling‐Ming Tseng, Guy Jérusalem, Sharon Wilks, Ruth O’Regan, Claudine Isaacs, Masakazu Toi, Howard A. Burris, Wei He, Douglas Robinson, Markus Riester, Tetiana Taran, David Chen, Dennis J. Slamon	135
17	Impact of prior anthracycline or taxane use on eribulin effectiveness as first-line treatment for metastatic breast cancer: results from two phase 2, multicenter, single-arm studies 2015 ·SpringerPlus ·Joyce O’Shaughnessy, Kristi McIntyre, Lee S. Schwartzberg, Sharon Wilks, Shannon Puhalla, (unknown), James Song, Linda T. Vahdat	14
18	Phase 2, Multicenter, Single-Arm Study of Eribulin Mesylate With Trastuzumab as First-Line Therapy for Locally Recurrent or Metastatic HER2-Positive Breast Cancer 2014 ·Clinical Breast Cancer ·Sharon Wilks, Shannon Puhalla, Joyce O’Shaughnessy, Lee S. Schwartzberg, (unknown), (unknown), David L. Cox, Linda T. Vahdat	50
19	Oral ezatiostat HCl (Telintra®, TLK199) and Idiopathic Chronic Neutropenia (ICN): a case report of complete response of a patient with G-CSF resistant ICN following treatment with ezatiostat, a glutathione S-transferase P1-1 (GSTP1-1) inhibitor 2011 ·Journal of Hematology & Oncology ·Roger M. Lyons, Sharon Wilks, (unknown), Gail L. Brown	18
20	The addition of hormone therapy to tamoxifen does not prevent hot flashes in women at high risk for developing breast cancer 2009 ·Breast Cancer Research and Treatment ·Cynthia R. Osborne, (unknown), Scot Sedlacek, Devchand Paul, Frankie A. Holmes, Svetislava J. Vukelja, (unknown), Sharon Wilks, (unknown), (unknown), Wally Meyer, Joyce O’Shaughnessy	8

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact